Head to Head Survey: eXoZymes (NASDAQ:EXOZ) and Erasca (NASDAQ:ERAS)

Erasca (NASDAQ:ERAS) and eXoZymes (NASDAQ:EXOZ) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Valuation and Earnings

This table compares Erasca and eXoZymes”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55 million	($0.93)	-19.69
eXoZymes	N/A	N/A	-$9.16 million	($1.14)	-5.05

Erasca is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

67.8% of Erasca shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 72.4% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Erasca and eXoZymes, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1	2	8	0	2.64
eXoZymes	1	0	0	0	1.00

Erasca currently has a consensus price target of $21.82, indicating a potential upside of 19.16%. Given Erasca’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Erasca is more favorable than eXoZymes.

Volatility & Risk

Erasca has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, eXoZymes has a beta of 2.93, indicating that its share price is 193% more volatile than the S&P 500.

Profitability

This table compares Erasca and eXoZymes’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
eXoZymes	N/A	-220.63%	-141.26%

Summary

Erasca beats eXoZymes on 7 of the 11 factors compared between the two stocks.

About Erasca

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

About eXoZymes

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.